Valrubicin-loaded immunoliposomes targeting antigens on immunosuppressive cells to circumvent resistance to cancer immunotherapy - PubMed
4 hours ago
- #immunosuppressive cells
- #nanoparticle therapy
- #cancer immunotherapy
- Development of valrubicin-loaded immunoliposomes (Val-ILs) to target immunosuppressive cells in cancer.
- In vivo screening identifies nine surface targets, including known and novel markers.
- Val-ILs reduce antigen expression on immunosuppressive and innate anti-tumor cells in the tumor microenvironment.
- Val-ILs enhance anti-PD-1 efficacy across four murine cancer models, including resistant types.
- Combination therapy increases CD4+ and CD8+ tumor-infiltrating lymphocytes and reprograms macrophages to M1-like phenotype.
- Val-ILs improve tumor control and reduce metastasis in resistant cancer models.